PAVmed Inc. entered into subscription agreements for the private placement of 13,625 series A convertible preferred stock at an issue price of $1,000 per share for gross proceeds of $13,625,000 on March 7, 2023. The transaction included participation certain accredited investors. In connection with the offering the company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | -4.50% | -8.62% | -74.27% |
May. 14 | Transcript : PAVmed Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 13 | PAVmed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-74.27% | 10M | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.98% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B |
- Stock Market
- Equities
- PAVM Stock
- News PAVmed Inc.
- PAVmed Inc. announced that it has received $13.625 million in funding